| Symbol | NRIX |
|---|---|
| Name | NURIX THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1700 OWENS STREET,SUITE 205, SAN FRANCISCO, California, 94158, United States |
| Telephone | +1 415 660-5320 |
| Fax | — |
| — | |
| Website | http://www.nurixtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001549595 |
| Description | Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The companys pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications. Additional info from NASDAQ: |
New Form SCHEDULE 13G/A - Nurix Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001104659-26-097194 <b>Size:</b> 13 KB
Read moreNew Form SCHEDULE 13G/A - Nurix Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001172661-26-003488 <b>Size:</b> 11 KB
Read moreNurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Read moreRing Christine 🟡 adjusted position in 16.6K shares (1 derivative) of Nurix Therapeutics, Inc. (NRIX) at $23.05 Transaction Date: Aug 03, 2026 | Filing ID: 000028
Read morevan Houte Hans 🟡 adjusted position in 2.8K shares (3 derivative) of Nurix Therapeutics, Inc. (NRIX) at $23.38 Transaction Date: Jul 30, 2026 | Filing ID: 000010
Read moreRing Christine 🟡 adjusted position in 3.8K shares (3 derivative) of Nurix Therapeutics, Inc. (NRIX) at $23.38 Transaction Date: Jul 30, 2026 | Filing ID: 000026
Read moreHansen Gwenn 🟡 adjusted position in 3.8K shares (3 derivative) of Nurix Therapeutics, Inc. (NRIX) at $23.38 Transaction Date: Jul 30, 2026 | Filing ID: 000012
Read moreNurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology
Read moreRing Christine 🟡 adjusted position in 11.0K shares (2 derivative) of Nurix Therapeutics, Inc. (NRIX) at $23.56 Transaction Date: Jul 02, 2026 | Filing ID: 000024
Read more📋 CHRISTINE RING (Officer) plans to sell 11K shares of NURIX THERAPEUTICS, INC. (at $23.91 each, total $263K) Filed: Jul 02, 2026 | ID: 006819
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07516093 | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL | Phase3 | B-cell Lymphoma | Not_Yet_Recruiting | 2026-06-01 | 2032-06-01 | ClinicalTrials.gov |
| NCT07520006 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Maligna… | Phase1 | B-cell Lymphoma | Not_Yet_Recruiting | 2026-05-01 | 2033-05-01 | ClinicalTrials.gov |
| NCT07221500 | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Ty… | Phase2 | Chronic Lymphocytic Leukemia (CLL) | Recruiting | 2025-10-15 | 2030-10-01 | ClinicalTrials.gov |
| NCT06717269 | A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, a… | Phase1 | Healthy Volunteer | Completed | 2024-11-30 | 2026-05-01 | ClinicalTrials.gov |
| NCT06691828 | Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance S… | Phase1 | Healthy Volunteer | Completed | 2024-11-01 | 2024-12-05 | ClinicalTrials.gov |
| NCT06593457 | A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in … | Phase1 | Healthy Volunteers | Completed | 2024-08-20 | 2024-11-14 | ClinicalTrials.gov |
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase1 | Chronic Lymphocytic Leukemia (CLL) | Recruiting | 2022-04-13 | 2028-01-01 | ClinicalTrials.gov |
| NCT05107739 | A Study of DeTIL-0255 in Adults With Advanced Malignancies | Phase1 | Platinum-resistant Ovarian Cancer | Terminated | 2021-12-22 | 2023-05-09 | ClinicalTrials.gov |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | Phase1 | Ovarian Cancer, Epithelial | Recruiting | 2021-09-29 | 2028-02-28 | ClinicalTrials.gov |
| NCT04830137 | A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Phase1 | Chronic Lymphocytic Leukemia (CLL) | Recruiting | 2021-05-05 | 2027-05-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| NX-5948 | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT07221500 |
| NX-5948 | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT07221500 |
| NX-5948 | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT07221500 |
| Quinidine | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06717269 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06717269 |
| Digoxin | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06717269 |
| Midazolam | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06717269 |
| Famotidine | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06717269 |
| Placebo | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06717269 |
| Esomeprazole | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06717269 |
| NX-5948 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06717269 |
| NX-5948 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT05131022 |
| NX-5948 | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT07221500 |
| NX-5948 | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT07221500 |
| NX-5948 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT05131022 |
| NX-5948 | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT07221500 |
| Drug Product De-TIL-0255 | Drug | Phase PHASE1 | Platinum-resistant Ovarian Cancer | TERMINATED | NCT05107739 |
| NX-5948 | Other | Phase PHASE1 | Healthy Volunteer | COMPLETED | NCT06691828 |
| Matching Placebo | Other | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06593457 |
| Paclitaxel | Other | Phase PHASE1 | Ovarian Cancer, Epithelial | RECRUITING | NCT05107674 |
| NX-1607 | Other | Phase PHASE1 | Ovarian Cancer, Epithelial | RECRUITING | NCT05107674 |
| Esomeprazole | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT06717269 |
| NX-5948 | Other | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT06717269 |
| NX-2127 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT04830137 |
| NX-5948 | Other | Phase PHASE2 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT07221500 |
| NX-5948 | Other | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT05131022 |
| Pirtobrutinib | DRUG | Phase PHASE3 | B-cell Lymphoma | NOT_YET_RECRUITING | NCT07516093 |
| Esomeprazole | DRUG | Phase PHASE1 | Healthy Volunteer | RECRUITING | NCT06717269 |
| Matching Placebo | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06593457 |
| IP | DRUG | Phase PHASE1 | Healthy Volunteers | COMPLETED | NCT06593457 |
| NX-5948 | DRUG | Phase PHASE3 | B-cell Lymphoma | NOT_YET_RECRUITING | NCT07516093 |
| Drug Product De-TIL-0255 | BIOLOGICAL | Phase PHASE1 | Platinum-resistant Ovarian Cancer | TERMINATED | NCT05107739 |
| Paclitaxel | DRUG | Phase PHASE1 | Ovarian Cancer, Epithelial | RECRUITING | NCT05107674 |
| NX-1607 | DRUG | Phase PHASE1 | Ovarian Cancer, Epithelial | RECRUITING | NCT05107674 |
| NX-2127 | DRUG | Phase PHASE1 | Chronic Lymphocytic Leukemia (CLL) | RECRUITING | NCT04830137 |